KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Castle Biosciences (CSTL) Shares Outstanding (2018 - 2025)

Castle Biosciences (CSTL) has disclosed Shares Outstanding for 8 consecutive years, with $29.7 million as the latest value for Q4 2025.

  • Quarterly Shares Outstanding rose 4.22% to $29.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $29.7 million through Dec 2025, up 4.22% year-over-year, with the annual reading at $29.7 million for FY2025, 4.22% up from the prior year.
  • Shares Outstanding hit $29.7 million in Q4 2025 for Castle Biosciences, up from $29.2 million in the prior quarter.
  • In the past five years, Shares Outstanding ranged from a high of $29.7 million in Q4 2025 to a low of $25.1 million in Q1 2021.
  • Historically, Shares Outstanding has averaged $27.1 million across 5 years, with a median of $26.8 million in 2023.
  • Biggest five-year swings in Shares Outstanding: soared 45.64% in 2021 and later rose 1.72% in 2022.
  • Year by year, Shares Outstanding stood at $25.4 million in 2021, then increased by 4.63% to $26.6 million in 2022, then grew by 3.23% to $27.4 million in 2023, then rose by 3.91% to $28.5 million in 2024, then rose by 4.22% to $29.7 million in 2025.
  • Business Quant data shows Shares Outstanding for CSTL at $29.7 million in Q4 2025, $29.2 million in Q3 2025, and $29.0 million in Q2 2025.